title: Opioids inhibit dopamine secretion from PC12 rat pheochromocytoma cells in a naloxone-reversible manner.
abstract: Opioids inhibit the release of catecholamines in the nervous system. Normal adrenal chromaffin cells produce delta opioids and they respond to them by suppressing the release of their catecholamines. Chromaffin cell tumors, the pheochromocytomas, produce mainly kappa opioids. The aim of this work was: (a) to test if pheochromocytomas retain the response of normal chromaffin cell catecholamines to delta opioids and to naloxone (a general opioid antagonist), and (b) to test if kappa opioids exert any specific effect on catecholamine release from these tumors. Since we have previously shown that, in common with human pheochromocytomas, the PC12 rat pheochromocytoma cells express the prodynorphin gene and secret its kappa opioid products, we used these cells to examine the effect of several opioid agonists and of naloxone on basal, nicotine-, and KCl-induced dopamine release. Dopamine is the main PC12 catecholamine. We have found that the specific kappa opioid agonist U-69593 inhibited the release of dopamine in a dose-dependent manner (IC50=0.5 x 10(-8)M). Under basal conditions the mean concentration of dopamine in the culture media was 11.25 +/- 0.57 ng/mg of total cellular protein (n=13). A 30 min exposure to U-69593 at 10(-6) M suppressed basal dopamine release to 58 +/- 2% (n=7) of controls. A 12 hr pre-incubation with U-69593 caused the same degree of suppression. The effect of the synthetic kappa opioid agonist dynorphin A was indistinguishable from that of U-69593. DADLE (a mu and delta synthetic opioid agonist) was significantly less effective in suppressing dopamine release (IC50=10(-7)M). The concentration of dopamine following exposure to 10-6 M of DADLE for 30 min was 74 +/- 5% of the controls (n=4). The mu opioid agonist DAGO was ineffective. The suppressive effect of all opioid agonists was blocked by naloxone suggesting that conventional opioid receptors were involved.
authors.affiliation: Department of Clinical Chemistry, School of Medicine, University of Crete, Iraklion, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Venihaki
authors.forename: A
authors.initials: A
authors.lastname: Gravanis
authors.forename: A N
authors.initials: AN
authors.lastname: Margioris
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003470:Culture Media; D004298:Dopamine / Q000378:metabolism*; D004563:Electrochemistry; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D016716:PC12 Cells; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D011957:Receptors, Opioid / Q000819:agonists
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid; D003470:Culture Media; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D009270:Naloxone; D009538:Nicotine; D011188:Potassium; D004298:Dopamine